Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of NS-229 in Eosinophilic Granulomatosis with Polyangiitis
jRCT2031230526Phase 2Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- May 2024
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in eosinophilic granulomatosis with polyangiitis (EGPA) comparing NS-229 with Placebo (2 arms). Primary endpoint: Remission with low-dose oral glucocorticoids at Week 28. Started May 2024; status: active, not recruiting.
02
Drugs
NS-229
03
Conditions
eosinophilic granulomatosis with polyangiitis (EGPA)
Beyond the preview
Go deeper on jRCT2031230526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230526.